ATYR 1940

Drug Profile

ATYR 1940

Alternative Names: ATYR1940; HRS(1-506); HRS(I-506); Resolaris

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator aTyr Pharma
  • Class Amino acyl-tRNA synthetases; Aminoacyltransferases; Biological proteins; Peptides; Proteins
  • Mechanism of Action Histidine-tRNA ligase modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Facioscapulohumeral muscular dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Facioscapulohumeral muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Facioscapulohumeral muscular dystrophy; Limb girdle muscular dystrophies
  • Preclinical Interstitial lung diseases

Most Recent Events

  • 13 Dec 2016 Safety and efficacy results from two phase Ib/II trials and an extension trial were released by aTyr
  • 24 Oct 2016 ATYR 1940 receives Fast Track designation for Facioscapulohumeral muscular dystrophy [IV,Infusion] (In adolescents, In adults) in USA
  • 06 Oct 2016 Efficacy data from a phase I/II trial in Facioscapulohumeral muscular dystrophy released by aTyr Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top